结直肠癌肝转移切除术后经导管辅助治疗(2)
时间:2021-07-02 14:58来源:www.ynjr.net 作者:杨宁介入医学网
研究二 Modern Systemic Therapy as Adjuvant Therapy after Liver Resection【2】 Between 2001-2005: 125 pts underwent resection of liver mets followed by HAI FUDR +SYS, compared to 125 consecutive pts w
研究二
Modern Systemic Therapy as Adjuvant Therapy after Liver Resection【2】
Between 2001-2005: 125 pts underwent resection of liver mets followed by HAI FUDR +SYS, compared to 125 consecutive pts who received Adj Folfox or Folfiri。
研究三：不同化疗方案的结果（HAI+ SYS- Overall Survival by Protocol）
|
|
Total |
Median OS (95%CI)(years) |
Median follow up(years) |
5 year OS
(95%CI)
|
|
HAI + SYS FOLFOX |
38 |
NA |
8.4 |
81% (65%-90%) |
|
HAI + SYS +/- Bev |
73 |
NA |
5.3 |
76% (63%-84%) |
|
HAI + SYS FU/LV |
70 |
6.3 |
18.8 |
60% (47%-70%) |
|
HAI + SYS CPT-11 |
103 |
6.6 |
12.2 |
58% (48%-67%) |
研究四： 根据Kras基因的生存率（ Survival (OS) by KRAS: Liver Resected Patients）
 |
 |
|
Adjuvant HAI+SYS（MSKCC）【3】
|
Adjuvant Sys（MD Anderson）【4】
|
Recurrence Free Survival (RFS) by KRAS Liver Resected Patients
 |
 |
|
Adjuvant HAI+SYS（MSKCC）【3】 |
Adjuvant Sys（MD Anderson）【4】 |
1. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005 Feb 17;352(7):734-5. |
------分隔线----------------------------
